观点：精准肿瘤学的错觉。 - Suppr

Perspective: The precision-oncology illusion.

作者信息

Prasad Vinay

机构信息

Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.

出版信息

Nature. 2016 Sep 8;537(7619):S63. doi: 10.1038/537S63a.

DOI:10.1038/537S63a

PMID:27602743

Abstract

摘要

相似文献

Perspective: The precision-oncology illusion.

Nature. 2016 Sep 8;537(7619):S63. doi: 10.1038/537S63a.

Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.

J Clin Oncol. 2020 Feb 1;38(4):351-358. doi: 10.1200/JCO.19.01573. Epub 2019 Dec 5.

Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.

Ann Oncol. 2019 Nov 1;30(11):1691-1694. doi: 10.1093/annonc/mdz392.

Next-Generation Sequencing in Oncology in the Era of Precision Medicine.

JAMA Oncol. 2016 Jan;2(1):13-4. doi: 10.1001/jamaoncol.2015.4503.

Perspective on Precision Medicine in Oncology.

Pharmacotherapy. 2017 Sep;37(9):988-989. doi: 10.1002/phar.1975. Epub 2017 Aug 7.

Delivering on the promise of precision cancer medicine.

Genome Med. 2016 Oct 25;8(1):110. doi: 10.1186/s13073-016-0373-1.

Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.

Health Aff (Millwood). 2018 May;37(5):751-756. doi: 10.1377/hlthaff.2017.1575.

The science of precision prevention of cancer.

Lancet Oncol. 2017 Aug;18(8):997-998. doi: 10.1016/S1470-2045(17)30331-5. Epub 2017 Jul 26.

Precision in psychiatry.

Acta Psychiatr Scand. 2015 Oct;132(4):310-1. doi: 10.1111/acps.12461. Epub 2015 Jul 3.

Personalized Medicine: Genomics Trials in Oncology.

Trans Am Clin Climatol Assoc. 2015;126:133-43.

引用本文的文献

Improving the Dosing Schedules of Targeted Anticancer Agents.

Pharmaceuticals (Basel). 2025 Jun 6;18(6):848. doi: 10.3390/ph18060848.

Establishing predictive machine learning models for drug responses in patient derived cell culture.

NPJ Precis Oncol. 2025 Jun 13;9(1):180. doi: 10.1038/s41698-025-00937-2.

Feasibility trial of Darwin OncoTreat and OncoTarget precision medicine testing to improve outcomes for patients with limited metastatic disease that failed first-line systemic therapy.

PLoS One. 2025 Jun 11;20(6):e0325769. doi: 10.1371/journal.pone.0325769. eCollection 2025.

A semi-supervised weighted SPCA- and convolution KAN-based model for drug response prediction.

Front Genet. 2025 Mar 21;16:1532651. doi: 10.3389/fgene.2025.1532651. eCollection 2025.

Prospective evaluation of structure-based simulations reveal their ability to predict the impact of kinase mutations on inhibitor binding.

bioRxiv. 2025 Mar 1:2024.11.15.623861. doi: 10.1101/2024.11.15.623861.

Prospective Evaluation of Structure-Based Simulations Reveal Their Ability to Predict the Impact of Kinase Mutations on Inhibitor Binding.

J Phys Chem B. 2025 Mar 20;129(11):2882-2902. doi: 10.1021/acs.jpcb.4c07794. Epub 2025 Mar 7.

Long-term survival and undetectable circulating tumor DNA following comprehensive involved site radiotherapy for oligometastases.

Sci Rep. 2025 Feb 19;15(1):6126. doi: 10.1038/s41598-025-88266-z.

Democratizing precision oncology with SCORPIO.

Nat Med. 2025 Mar;31(3):741-742. doi: 10.1038/s41591-025-03514-z.

The systemic evolutionary theory of the origin of cancer (SETOC): an update.

Mol Med. 2025 Jan 14;31(1):12. doi: 10.1186/s10020-025-01069-w.

A precision immuno-oncology turn? Hybridizing cancer genomics and immunotherapy through neoantigens-based adoptive cell therapies.

Soc Stud Sci. 2025 Aug;55(4):565-590. doi: 10.1177/03063127241303720. Epub 2024 Dec 15.

本文引用的文献

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

JAMA Oncol. 2016 Nov 1;2(11):1452-1459. doi: 10.1001/jamaoncol.2016.2129.

Characteristics of Exceptional or Super Responders to Cancer Drugs.

Mayo Clin Proc. 2015 Dec;90(12):1639-49. doi: 10.1016/j.mayocp.2015.08.017. Epub 2015 Nov 3.

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.

J Clin Oncol. 2015 Sep 1;33(25):2753-62. doi: 10.1200/JCO.2014.60.4165. Epub 2015 May 26.

Genome sequencing identifies a basis for everolimus sensitivity.

Science. 2012 Oct 12;338(6104):221. doi: 10.1126/science.1226344. Epub 2012 Aug 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Perspective: The precision-oncology illusion.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献